Psoriasis would also be an excellent target for Treg's.
I also agree that if Treg's are proven to be efficacious for any autoimmune condition, there will be a stampede to develop therapies in multiple conditions. Any of the companies developing allogeneic CAR T cells for cancers may also enter the autoimmune field (except Gilead since that was part of our partnership).
My hope is that many of these companies will already have significant resources tied up in these oncology trials to allow Sangamo to secure a lead in the biggest autoimmune indications.